DEEP BRAIN STIMULATION DEVICES MARKET ANALYSIS

Market Challenges And Opportunities

• The associated risks involved with deep brain stimulation procedures like misplacement of leads and bleeding in the brain

• High prevalence of diseases such as Parkinson’s disease and epilepsy
• Frequent approval and launch of novel devices

Frequent approval and launch of novel devices is expected to fuel the global deep brain stimulation devices market growth

Key players in the market are focused on approval and launch of novel DBS devices to expand their product portfolio, which is expected to boost the market growth. For instance, in January 2019, Boston Scientific Corporation launched two new DBS devices namely the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) systems.

Figure 2. Global Deep Brain Stimulation Device Market Share (%), by Region, 2022

Global Deep Brain Stimulation Devices Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals. Manufacturers have found it difficult to serve their surgeon customers since some hospitals have restricted access to their facilities or changed access regulations. For instance, in December 2020, according to the report of National Center of Biotechnology Information, lockdown restriction measures were associated with subjective worsening of motor and psychiatric symptoms like significant tiredness, low energy or problems sleeping in Parkinson Disease and dystonic patients treated with DBS, and they may have exacerbated the burden of neurological disease and increased the chronic stress related to the DBS management.

Global Deep Brain Stimulation Devices Market: Key Developments

• Increasing adoption of new technologies in the hospitals is expected to drive the growth of global deep brain stimulation devices market, according to press released by MGM Healthcare in February 2020, the MGM Healthcare, Tamil Nadu, performed first Deep Brain Stimulation (DBS) surgery for Obsessive Compulsive Neurosis or OCD, a mental illness.
• Moreover, increasing number of prevalence of Parkinson’s Disease is expected to drive the growth of global deep brain stimulation devices market, according to a study report published by Parkinson’s Disease Society of the United Kingdom in 2022, it was estimated that the rate of prevalence in 2017, was 1-2 people in every 100,000 aged 20-29 and 4 or 5 people in every 100,000 aged 30-39. Prevalence increased with age with the prevalence for those aged 80-84 being 1,696 per 100,000 people which is equivalent to around 1.7% of this age-group in the U.K.
• For instance, in January 2021, BrainsWay Ltd., a global advanced non-invasive treatment of brain disorders, announced an exclusive distribution agreement with Gaelan Medical Trade LLC, healthcare company with extensive distribution channels in the U.A.E. The agreement establishes a multiyear framework whereby BrainsWay will supply its patented, revolutionary Deep Transcranial Magnetic Stimulation (Deep TMS) system, which is currently marketed in various markets for brain disorders including major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), to now be marketed and sold throughout the U.A.E.